Editorial: “Recent advances in gamma/delta T cell biology: new ligands, new functions, and new translational perspectives” by Dieter Kabelitz
EDITORIAL
published: 21 July 2015
doi: 10.3389/fimmu.2015.00371
Edited by:
Rene De Waal Malefyt,
Merck Research Laboratories, USA
Reviewed by:
Luis Alejandro Zuniga,
Merck Research Laboratories, USA
*Correspondence:
Dieter Kabelitz
dietrich.kabelitz@uksh.de
Specialty section:
This article was submitted to T Cell
Biology, a section of the journal
Frontiers in Immunology
Received: 09 May 2015
Accepted: 06 July 2015
Published: 21 July 2015
Citation:
Kabelitz D and Déchanet-Merville J
(2015) Editorial: “Recent advances in
gamma/delta T cell biology: new
ligands, new functions, and new
translational perspectives”.
Front. Immunol. 6:371.
doi: 10.3389/fimmu.2015.00371
Editorial: “Recent advances in
gamma/delta T cell biology: new
ligands, new functions, and new
translational perspectives”
Dieter Kabelitz1* and Julie Déchanet-Merville2
1 Institute of Immunology, University of Kiel, Kiel, Germany, 2 CNRS UMR 5164, Université de Bordeaux, Bordeaux, France
Keywords: gd T cells, infection, tumor immunity, phosphoantigen, IL-17
Since their discovery in the mid-1980s, interest in the immunological significance of γδ T cells has
been subject to oscillations. The initial excitement over the unexpected discovery of a second T
cell receptor (TCR) was followed by years of uncertainty as to the biological importance of these
ambivalent T cells. Major breakthroughs led to the identification of specific and unique antigens
for the γδ TCR and accumulating evidence now shows that γδ T cells play a major role in local
immunosurveillance, thereby controlling tumorigenesis. Since 2004, biannual international γδ T
cell conferences are held to bring together experts in basic and clinical γδ T cell research. To
make accessible and synthesize the body of knowledge that has been put together, to date, we have
organized a “Research Topic” on γδ T cells consisting of a collection of original articles and focused
reviews written by leading experts in the field. The idea of this Research Focus was to present the
current status and “hot topics” as well as clinical perspectives on γδ T cell research.
gd T Cells: Differentiation, Activation, and Signaling
The signaling pathways governing γδ T cell differentiation and activation have been discussed
in contributions from Carl Wares’s (1) and Bruno Silva-Santos’s (2) groups. Ribeiro et al. discuss
the control of γδ T cell activation and differentiation by distinct classes of cell surface receptors,
namely (i) the TCR, (ii) costimulatory receptors (with a focus on CD27), (iii) cytokine receptors,
(iv) NK receptors, and (v) inhibitory receptors. They further summarize how activation of γδ T
cells can be controlled by the TCR as well as by activating NK receptors. To terminate γδ T cell
responses, several inhibitory receptors can deliver negative signals, notably PD-1 and B- and T-
lymphocyte attenuator (BTLA) (2). Bekiaris et al. focus on the cytokine control of innate γδ T cells,
and discuss the role of IL-7 in being critical for thymic development of γδ T cells by regulating the
survival of progenitor cells and inducing V(D)J recombination within the TCRγ gene locus. IL-7
also supports homeostatic proliferation of γδ T cells and regulates surface expression of BTLA in a
STAT5-dependent manner (1).
In recent years, IL-17 has been identified as an essential cytokine that regulates the recruitment of
neutrophils during an inflammatory response. IL-17 must be rapidly available in an acute infection.
αβ T cells producing IL-17 (Th17 cells) require specific antigenic stimulation and an appropriate
cytokine milieu for differentiation. γδ T cells have been identified as an important “innate” source
of rapid initial IL-17 production, which is thought to occur without specific TCR triggering (3).
Several years ago, the group of Immo Prinz generated a unique mouse model to monitor early steps
of γδ T cell development (4). Using these reporter mice, they demonstrated that IL-17 producing
γδ T cells develop during the embryonic period and persist in adult mice as self-renewing, long-
lived cells (5). Interestingly, Wei and colleagues have provided evidence that the TCR repertoire
of such naturally occurring IL-17-producing murine γδ T cells is highly restricted, with little
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or no junctional diversity, regardless of their anatomical ori-
gin. These findings strongly suggest that antigen recognition is
involved in the establishment and/or function of such “innate” IL-
17 producing γδ T cells (6). Further aspects of IL-17 producing
γδ T cells, also addressing their role in various pathophysiological
conditions, are discussed in the review article by Patil et al. (7).
In addition to production of cytokines, such as IL-17, γδ T
cells can induce maturation of dendritic cells (DCs) and B cells.
Petrasca andDoherty report on the upregulation of the expression
of CD86, HLA-DR, IL-6, and TNFα in both DC and B cells upon
coculture with human Vγ9Vδ2 T cells, whereas other cytokines,
such as IFNγ or IL-4, were differentially induced in DC versus
B cells (8). Collectively, their data indicate that γδ T cells can
drive the expression of antigen presenting cell (APC)-associated
markers in both DC and B cells (8). Interaction with neighboring
cells is a key feature of γδ T cells. This is particularly true for
tissue-resident γδ T cells. Witherden et al. have reviewed the mul-
tiple molecular interactions that have been characterized between
skin-resident dendritic epidermal γδ T cells and keratinocytes.
Among their many effector functions, epidermal γδ T cells are
involved in wound repair, maintenance of epithelial homeostasis,
and protection from malignant transformation (9).
A final aspect of γδ T cell differentiation and plasticity is
presented in the report of Ziegler et al. (10). These authors made
the surprising observation that the small population of human
peripheral blood Vδ1 γδ T cells that simultaneously express CD4,
can differentiate into bona fide αβ T cells in a process called
transdifferentiation. The authors took all measures to avoid the
potential contribution of possible artifacts that may influence
their results. Their characterization of humanCD4+Vδ1 γδTcells
as a source of extrathymic T cell development challenges current
dogmas and opens interesting avenues for future research (10).
Recognition of Pyrophosphate Antigens
by Human gd T Cells
A particularly exciting new area of γδ T cell research is the role
of butyrophilin and butyrophilin-like molecules (which consist
of all members of the B7 family of co-stimulators) in γδ T cell
activation. A member of this family, Skint-1, has been shown
as critical for positive selection of mouse Vγ5Vδ5 dendritic epi-
dermal T cells (11). In humans, Butyrophilin 3A1 (BTN3A1)
was recently found to play a critical role in the activation of
Vγ9Vδ2 T cells by pyrophosphate molecules – collectively termed
as “phosphoantigens” (pAgs). These intermediates of the eukary-
otic mevalonate and the prokaryotic non-mevalonate pathway
for isoprenoid synthesis have been identified as specific lig-
ands for the Vγ9Vδ2 TCR that activate this subset of T cells at
pico- to nanomolar (microbial pAgs) or micromolar (eukaryotic
pAgs) concentrations. The recognition of metabolites that are
produced by microbes [e.g., (E)-4-hydroxy-3-methyl-but-2-enyl
pyrophosphate (HMBPP)] or that are overproduced by trans-
formed eukaryotic cells [e.g., isopentenyl pyrophosphate (IPP)]
provides a formal basis for the role of Vγ9Vδ2 T cells in both
anti-infective and anti-tumor immunity (12). Interestingly, the
recognition of non-peptidic small molecules is not restricted to
human γδ T cells. As an example, Zeng et al. recently reported
that small molecules, such as haptens, are recognized by specific
murine γδ TCRs (13).
For many years, it has been enigmatic how pAgs are actually
recognized by the human γδ TCR, and whether any “presenting”
molecules are involved. A major breakthrough was the identi-
fication of an agonistic monoclonal antibody (called 20.1) that
specifically triggers Vγ9Vδ2 T cell activation among peripheral
blood mononuclear cells in a manner that is very similar to pAgs.
This antibody is directed against CD277, a member of the B7
superfamily of butyrophilin (BTN) molecules. Detailed studies by
Harly et al. identified an indispensable role of the BTN3A1 iso-
form in the activation of Vγ9Vδ2 T cells by pAgs (14). BTN3A1 is
a transmembranemolecule with two Ig-like extracellular domains
and an intracellular B30.2 domain. This discovery of the essen-
tial function of BTN3A1 in Vγ9Vδ2 T cell activation stimulated
further research, particularly addressing the question whether
BTN3A1 is directly involved in “presenting” pAgs to the γδ TCR.
In continuation of the above studies, Gennaro de Libero’s group
has come up with new evidence that suggests the Ig-like extracel-
lular domain of BTN3A1 can directly bind pAgs and that there is
specific and direct interaction of soluble Vγ9Vδ2 TCR with the
BTN3A1–pAg complex (15). Quite surprisingly, however, such a
“presenting” function of the extracellular BTN3A1 domain could
not be verified by Erin Adam’s group. Instead, Adam and col-
leagues corroborated there being a crucial role of the intracellular
B30.2 domain, which may actually directly interact with pAgs
(16). In their model, the intracellular B30.2 domain might sense
increased levels of intracellular pAgs (due to infection or cellular
transformation), possibly inducing a conformational change in
the BTN3A1 molecule, which could then be recognized by the
Vγ9Vδ2 TCR (16). However, the issue appears to be even more
complicated. Using CHO cells reconstituted with chromosome
6 as the only source of human genes, Riaño et al. demonstrate
a potential role of other genes on chromosome 6 in addition
to BTN3A1 that work to activate human Vγ9Vδ2 T cells (17).
The various proponents of the seemingly conflicting models on
the capacity of extra- versus intracellular BTN3A1 domains to
directly interact with pAgs provide a balanced overview on this
controversial issue in this special Research Topic (18–20).
Beyond this, “the intracellular pAg sensing model” recently
received additional support from John Trowsdale’s group. These
authors also reported direct binding ofHMBPP to the intracellular
B30.2 domain (21). Furthermore, using a yeast-two hybrid screen,
theses authors determined that the cytoskeletal protein plakin
interacts with the cytoplasmic tail of BTN3A1 in a region proximal
to the B30.2 domain. Such protein–protein interactions might be
crucial in transmitting signals (e.g., conformational alterations of
BTN3A1) from the γδ TCR upon pAg binding to the intracellular
B30.2 domain (21). It is thus evident that many of the mechanistic
details of BTN3A1 are still unclear, beyond the undisputed fact
that it is indispensable for γδ T cell activation by pAgs.
Intriguingly, the mouse lacks BTN3A1 genes and homologous
γδTCR thatwould be able to recognize similar pAgs. Karunakaran
and Herrmann (22) have studied the ontogenetic evolution of
Vγ9, Vδ2, and BTN3 genes. Their detailed database analysis sug-
gests that these three genes have co-evolved in placental mam-
mals, while they are lost in rodents and lagomorphs (22). Taken
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together, the controversial issue of the ménage à trois of Vγ9Vδ2
TCR, pAgs, and BTN3A1 awaits additional elucidation. We are
grateful that the major players in this particular field have shared
their results and thoughtful reflections for this Research Topic.
gd T Cells in Tumor Immunity
γδ T cells can kill a broad range of tumors of epithelial origin as
well as many leukemias and lymphomas, and are further able to
produce high levels of the anti-tumor cytokine, IFNγ. Given their
HLA non-restricted method of ligand recognition, the role of γδ
T cells in anti-tumor immunity has stimulated great interest to
explore their potential for cancer immunotherapy (23). Interest-
ingly, the production of endogenous pAgs, such as IPP, can be
pharmacologically manipulated by nitrogen-containing bispho-
sphonates (N-BP), which inhibit the downstream processing of
IPP, leading to increased levels of endogenous IPP that is sensed
by Vγ9Vδ2 T cells (24). Based on this knowledge, intravenous
application of the N-BP zoledronate together with low-dose IL-
2 has been evaluated as a means of in vivo activation of γδ T cells
in cancer patients (25). A recent survey has reviewed the available
published studies on the in vivo activation and adoptive transfer
of γδ T cells in cancer patients (26). Most likely, strategies aiming
to activate γδ T cells in vivo will have to be combined with other
treatment regimens to obtain optimal anti-tumor activity (27).
In addition to IPP and related pAgs, which serve as antigens
for tumor-reactive Vγ9Vδ2 T cells, several cell surface-expressed
antigens have been identified for tumor-reactive human non-
Vδ2 γδ T cells. One example illustrating the versatility of γδ T
cells is the endothelial protein C receptor (EPCR), which is an
HLA-related molecule. We (Déchanet-Merville group) identified
EPCR as a target for non-Vδ2 γδ T cells that is expressed on
endothelial cells infected by cytomegalovirus (CMV) and is also
similarly expressed on epithelial tumor cells (28). It is thus con-
ceivable that non-Vδ2 γδT cells have a similar potential for cancer
immunotherapy as pAg-reactive Vδ2 T cells (23, 29). The recent
discovery that CD1d, the closest structural homolog of EPCR, can
present self lipids to the human Vδ1 TCR, also deserves further
investigations in the domain of γδ T cell-mediated anti-tumor
protection and function (30, 31). It should be borne in mind that
the anti-tumor efficacy of γδ T cell subsets (Vγ9Vδ2, non-Vδ2)
may, of course, vary between different tumor entities (32).
One of the basic observations supporting a role of immune
surveillance in tumor development and progression is the sticking
correlation between the proportion of tumor-infiltrating CD3+
T cells (TIL) and tumor progression and patient survival (33).
γδ T cells can represent a significant proportion of CD3+ TIL
in different tumors (34, 35). Hidalgo et al. analyzed the presence
of γδ T cells among TIL in different types of breast carcinoma.
Their results suggest a correlation between higher numbers of
γδ TIL and a better prognosis in medullary breast carcinoma
as compared to invasive ductal carcinomas, two subtypes of the
Her2- and hormone receptor-negative (“triple-negative”) breast
carcinoma (35).
It is clear, however, that an increased presence of γδ T cells
within a tumor per se is not necessarily associated with a beneficial
effect. As discussed by Lo Presti et al., there are multiple inter-
actions of tumor-infiltrating γδ T cells within the local tumor
microenvironment that strongly influence the functional outcome
(36). Relevant factors include (but are not restricted to) tumor-
derived immunosuppressive cytokines, such as TGF-β, locally
expressed inhibitory molecules, such as PD-1, and myeloid-
derived suppressor cells (MDSCs) located within the tumor
stroma (36). Moreover, tumor-infiltrating γδ T cells themselves
may exert suppressive activity (37) or promote the accumulation
of MDSCs (38). Pro-tumoral activity of γδ T cells has also been
demonstrated in several mouse models, and this is mainly medi-
ated through their production of IL-17, which, in these instances,
results in the attraction of immunosuppressive myeloid cells and
promotion of angiogenesis. Depending on the priming signals
in the tumor microenvironment, in addition to other γδ T cell
subtypes, even pAg-reactive Vγ9Vδ2 T cells may acquire sup-
pressive activity (39). In the context of tumor immunity, multiple
scenarios may thus convert γδ T cells into suppressive cells, which
can have counter-productive consequences for tumor immunity
(40). Taken together, γδ T cells can exert both anti- and pro-
tumorigenic activities, and it is amajor challenge for future studies
to determine how to specifically boost the anti-tumor effects of
γδ T cells while simultaneously shunting their suppressive activity
(41). This functional plasticity of mouse and human γδ T cells in
the anti-tumor immune response has been extensively discussed
by Lafont et al. (42).
To enhance the anti-tumor activity of γδ T cells, several strate-
gies are under consideration. These include the use of antibodies
to trigger Fc receptor-dependent ADCC, or the use of bispecific
antibody constructs to cross-link the γδ TCR with tumor cell
surface antigens. Seidel et al. have explored Fc-optimized anti-
CD19 antibodies as well as CD19/CD16 bispecific antibodies to
enhance γδ T cell-mediated killing of CD19+ B cell malignan-
cies (43). For this purpose, they employed a label-free real-time
cytotoxicity assay, which allows monitoring the tumor cell–γδ T
cell interactions over prolonged periods of time (43). This system
was also used by us (Kabelitz group) to demonstrate the efficacy
of a Her2-Vγ9 “tribody” construct in enhancing lysis of Her2-
expressing pancreatic adenocarcinoma cells by Vγ9Vδ2 effector
T cells (34). A different approach to explore the potential use of
γδ T cells for cancer immunotherapy would be to develop γδ T
cell-based cancer vaccines. This strategy is based on the seminal
discovery of Bernhard Moser’s group that found activated human
Vγ9Vδ2 T cells may actually serve as “professional” APCs that
pick up and process exogenous antigens and load them onto both
MHC class II andMHC class I presentation pathways for recogni-
tion by CD4+ and CD8+αβ T cells, respectively (44). Toward this
end, the capacity of activated human γδ T cells to take up tumor-
derived antigens and to present processed peptides to tumor
antigen-specific CD8+αβ T cells has been demonstrated (45). As
discussed by Khan et al., the ease with which Vγ9Vδ2 T cells are
expanded into large numbers in vitro offers an innovative strategy
for the development of γδ T cell-based tumor vaccines (46).
For the adoptive transfer of in vitro expanded γδ T cells, a
multitude of experimental protocols have been developed. One
important aspect to bear in mind for this procedure is to design
means to fully polarize γδ T cells toward an efficient anti-tumor
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functionality. Promotion of their IFNγ expression instead of IL-17
will certainly be an important step toward this aim (41). Along this
line, Deniger and coworkers have summarized various strategies
of in vitro expansion and further discuss additional perspectives
involving genetic approaches to increase the efficacy of γδ T cell-
based immunotherapy (47). A crucial point in this context is the
efficient monitoring of γδ T cell subpopulations in the blood of
cancer patients. We (Kabelitz group) have established a system
to accurately determine absolute numbers of circulating Vδ1 and
Vδ2 γδ T cells from a small sample of whole blood. This method
enabled us to determine a threshold number of Vδ2 T cells per
microliter blood below which no cytotoxic activity toward pan-
creatic adenocarcinoma tumor targets could be triggered by pAg
or Her2-Vγ9 tribody (48). Another important step for the appli-
cation of γδ T cell-based immunotherapy involves identifying the
antigenic ligands recognized by γδ T cells on tumor cells as they
may potentially be used as agonistic drugs either ex vivo for γδ
T cell expansion or in vivo for active vaccination trials. Together,
the collection of papers published in this Research Topic discuss
critical issues pivotal for understanding the precise role of γδ T
cells in tumor immunosurveillance or tumor immune evasion
as well as highlighting the future potential of γδ T cell-based
immunotherapies.
gd T Cells in Infection and Other Diseases
In view of the strong activation of human Vγ9Vδ2 T cells by
microbial pAgs (notably HMBPP), it is not surprising to see
significant expansion of peripheral blood γδ T cells during the
acute phase of many infections (49). However, not all microbes
produce such γδ T cell-stimulating molecules. The differential
production of γδ T cell ligands by microbes can be used for
diagnostic purposes to identify the presence of (mostly Gram-
negative) bacteria and thus allow for a pathogen-specific immune
fingerprinting. This inventive diagnostic application of γδ T cell
research in the context of infectious diseases is highlighted in the
Opinion Article by Eberl et al. (50).
While Vγ9Vδ2 T cells increase in numbers in many bacterial
and parasitic infections, these cells are characteristically reduced
in HIV infected individuals. Even upon efficient anti-retroviral
therapy and CD4 T cell reconstitution, Vγ9Vδ2 T cell numbers
usually remain low. Pauza and colleagues discuss the potential
consequences of persistent low Vγ9Vδ2 T cell numbers in HIV
infected individuals and argue in favor of designing innovative
clinical trials to reconstitute normal levels of Vγ9Vδ2 T cells (51).
Another example of viral infection with high relevance for γδ T
cells is CMV. Our (Déchanet-Merville group) early studies have
uncovered a remarkable expansion of Vδ2-negative γδ T cells
in CMV-positive but not -negative kidney transplant recipients
(52). Further studies have revealed multiple possible functions
of CMV-induced γδ T cells, including direct anti-viral activity.
Concomitant studies in mouse models point to a protective role
of murine γδ T cells against CMV infection (53, 54). All these
aspects including the cross-reactivity of CMV-reactive non-Vδ2
γδ T cells with certain epithelial tumor entities are discussed in a
review article by Couzi et al. (55).
This Research Topic also addresses the role of γδ T cells
in non-infectious diseases. In addition to infection and cancer,
autoimmune diseases, and wound healing and burn injuries have
been addressed by Latha et al. (56). This review summarizes the
extensive evidence showing the involvement of γδ T cells in many
pathophysiological conditions. An interesting specific example is
reported by Marcu-Malina and coworkers (57) who observed a
TNF-dependent induction of procoagulant tissue factor-1 (TF-1)
inmonocytes by zoledronate-stimulated γδT cells. This seemed to
occur specifically in γδ T cells from patients with systemic sclero-
sis (57). Last but not least, this Research Topic additionally covers
the role of γδ T cells in the diagnosis of immunodeficiencies. TCR
immunodeficiencies can affect both αβ and γδ T cells. While αβ
T cells have been extensively studied, γδ T cells are frequently
ignored, partly due to their numerical scarcity in circulation.
Garcillán et al. discuss these issues in detail and present a useful
diagnostic flowchart (58).
Concluding Remarks
After 30 years of γδ T cell research, it is clear that these cells are
intimately involved in the control of tissue homeostasis, infection,
and malignancy. The identification of specific ligands for the γδ
TCR provides strong support for the idea that γδ T cells are
non-redundant to αβ T cells. Apart from the detailed knowl-
edge of their physiological and pathophysiological significance,
we are currently experiencing new exciting developments aimed
at bringing γδ T cells into clinical medicine.
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